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THE JOHN WESLEY POWELL STUDENT RESEARCH CONFERENCE - APRIL 2011 
Oral Presentation 01.2 
R&D INVESTMENT LINK TO PROFITABILITY: 
A PHARMACEUTICAL INDUSTRY EVALUATION 
Lawrence J. Nord and Haria Ossella-Durbal* 
Economics Department, Illinois Wesleyan University 
This paper is an in depth analysis of the influence that investment into research and development 
has on a firm's profitability in the pharmaceutical industry in the United States. The 
pharmaceutical industry is chosen due to its high intensity of research and development 
expenditures. The top 18 companies in the pharmaceutical industry are gathered and organized as 
panel data dating over the recent regression, which encompassed three years. The data are 
analyzed through regression and descriptive statistics. 
The argument made is that as more funds are invested into research and development a firm in 
the pharmaceutical industry will experience a higher market value. Theoretically as firms spend 
more on research and development they are increasing the likelihood of innovation, which will 
cause growth in the company. The results of this study agree, and a positive and significant 
relationship is found between research and development expenditures and market value. 
